Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.
about
A systematic review of modelling approaches in economic evaluations of health interventions for drug and alcohol problemsEstimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis.Can we build an efficient response to the prescription drug abuse epidemic? Assessing the cost effectiveness of universal prevention in the PROSPER trial.The impact of dispensing fees on compliance with opioid substitution therapy: a mixed methods study.An organizational readiness intervention and randomized controlled trial to test strategies for implementing substance use disorder treatment into primary care: SUMMIT study protocol.Access to Addiction Pharmacotherapy in Private Health Plans.The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trialShort term health-related quality of life improvement during opioid agonist treatmentPolicies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence.Public sector low threshold office-based buprenorphine treatment: outcomes at year 7.Buprenorphine-naloxone therapy in pain management.The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.Collaborative Care for Opioid and Alcohol Use Disorders in Primary Care: The SUMMIT Randomized Clinical Trial.Cost-effectiveness of subdermal implantable buprenorphine versus sublingual buprenorphine to treat opioid use disorder.Economic Evaluations of Opioid Use Disorder Interventions.Commercial Health Plan Coverage of Selected Treatments for Opioid Use Disorders from 2003 to 2014.Substance Use Treatment Provider Behavior and Healthcare Reform: Evidence from Massachusetts.Impact of early childhood trauma on retention and phase advancement in an outpatient buprenorphine treatment program.Barriers to medical provider support for prescription naloxone as overdose antidote for lay responders.Adherence to Buprenorphine Treatment Guidelines in a Medicaid Program.A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.Characterizing Long-Term Health Related Quality of Life Trajectories of Individuals With Opioid Use DisorderSex Differences in Regional Brain Glucose Metabolism Following Opioid Withdrawal and Replacement.Assessing and improving organizational readiness to implement substance use disorder treatment in primary care: findings from the SUMMIT study.Implementing the Chronic Care Model for Opioid and Alcohol Use Disorders in Primary Care.Effects of motivational interviewing fidelity on substance use treatment engagement in primary care.Sustaining alcohol and opioid use disorder treatment in primary care: a mixed methods study.Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder
P2860
Q28072735-62E92096-E4C7-4BEB-8003-BD9CEB971CDEQ33724701-9E83D4E6-74D8-4B3D-979A-8248517874B0Q34041421-B60C83A2-3375-489A-8224-0B2210D126F7Q34059799-A467E69B-B43F-4682-9A94-C96ECC4CE8D5Q35609744-B0C6CBF9-8013-40EE-84EA-0A86571D5F01Q36025907-6CC9A28F-C52A-418F-8F3A-5F173AF93ACAQ36536506-A64E6ABB-9804-471C-B01C-A3BF5FA0DC84Q36652120-4B195CF7-ED91-4C47-A07F-4B0A16D8EADAQ36711790-693D7915-CCA7-4030-AFC2-6B8F6EE37DABQ37663311-9B479397-1F6B-4D24-8B43-D3C882478A16Q37673456-3280EB6A-961A-4D58-B96B-75B45F0A91F0Q37722356-19A5A2E3-B76A-4BC2-A751-AFCF4433815CQ38167693-DC4D0509-BFED-448B-8977-9DBD8E314F2BQ38371596-A73DCFE9-DC1D-4CFD-A4F8-96B6720C979CQ38730784-6BECE3BE-F994-4961-A6F0-8FF73FE50564Q38784603-63A9E0FA-3C81-482E-843B-84BAFA8CCBA0Q38871365-44E91A51-CD3B-4C89-B84B-5DE4C04773FAQ38948653-D8F58E88-98BF-4746-B69B-7F7CCF65D266Q39388932-0CC6A081-977B-4D20-AF27-AEF70CF5C215Q39424322-51533EA1-189D-4946-9CCB-6A9D63E54C22Q41367554-998CE89C-FEEB-463A-9654-18046788FC83Q42219124-743DF62A-435A-4E9D-ADCC-700F513173F2Q42709317-ACFF77EE-17E1-4D43-9E37-3EBA20158FCDQ44344766-D9B7F5F3-3CA3-48B5-A84B-9475CE55F60EQ47130417-26E893CC-058E-4D23-9509-6DDD5758B852Q48538117-064768B4-8F80-4B58-942A-5358FA191AB7Q52689409-4A303395-FB53-4C39-80C7-C7BF5720EE6AQ55311627-926B1B8E-A706-48C9-9C12-58CFCB726C95Q57492671-B3B6244C-1F9C-492B-8EFF-7B53AEE04713
P2860
Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cost-effectiveness of long-ter ...... id dependence in primary care.
@ast
Cost-effectiveness of long-ter ...... id dependence in primary care.
@en
type
label
Cost-effectiveness of long-ter ...... id dependence in primary care.
@ast
Cost-effectiveness of long-ter ...... id dependence in primary care.
@en
prefLabel
Cost-effectiveness of long-ter ...... id dependence in primary care.
@ast
Cost-effectiveness of long-ter ...... id dependence in primary care.
@en
P2093
P2860
P1476
Cost-effectiveness of long-ter ...... id dependence in primary care.
@en
P2093
Bruce R Schackman
Daniel Polsky
Jared A Leff
P2860
P2888
P304
P356
10.1007/S11606-011-1962-8
P577
2012-01-04T00:00:00Z